In a significant market move, OrbiMed, a US-based investment firm, sold a 2.27% stake in Marksans Pharma for Rs 257 crore through an open market transaction. The stake, amounting to over 1.02 crore shares, was sold at an average price of Rs 249.95 per share, reducing OrbiMed's holding in the pharmaceutical company to 8.61%. The transaction, valued at Rs 256.78 crore, saw notable buyers including Citigroup, Societe Generale, and several mutual funds. Following the sale, Marksans Pharma's share price rose by 5.62%, closing at Rs 264 on the NSE, signaling strong investor interest.